Cell therapy appeared on the national and local sessions in 2022, the era of cell industry has come

Recently, the 2022 NPC and CPPCC sessions have been opened, and the development of cell therapy industry in Beijing, Shanghai, Hunan, Dalian and other places has attracted much attention, and in this special period of this year, it is even more expected by the public.

Lu Hongbing, a member of the CPPCC National Committee, proposed setting up a special zone for the development and application of stem cell and gene diagnosis and treatment technologies.

The fifth session of the 13th National Committee of the Chinese People's Political Consultative Conference (CPPCC) opened at the Great Hall of the People in Beijing on March 4, 2018. Lu Hongbing, a member of the National Committee of the Chinese People's Political Consultative Conference (CPPCC), said in an interview on the eve of the two sessions that he will propose setting up a "special zone for the development and application of stem cells, gene diagnosis and treatment technology" and opening up international capital to participate in the field of stem cells and gene technology.

On March 3, before the upcoming national two meetings in 2022, the CPPCC national committee Lv Hongbing said in an interview with the first finance and economics, in order to accelerate the biological medicine industry development in our country, the Suggestions on the one hand, the stem cell, gene diagnosis, and treatment technology development and application domain moderate open diversification, on the other hand, the elaboration and optimization of the country in policy, Special attention and treatment will be given to enterprises independently researching and developing new drugs, especially biomedicine.
In his proposal, Lu suggested that more detailed "detailed rules" could be formulated to fully protect and promote the research and development of China's independent innovative drugs. For example, a longer tolerance period will be given to the independent research and development of new drugs, especially biomedicine, by enterprises in line with cutting-edge innovative technologies. That is, enterprises should independently decide whether to enter the centralized procurement catalog and the price discount space to enter the centralized procurement catalog, so as to encourage more market players to invest in the development of innovative drugs and encourage global scientific and technological talents to gather in China's innovative drug enterprises.
With the improvement of people's living standard, the aging society has brought a high incidence of tumors and degenerative diseases. The investment and research and development of stem cell and gene technology are related to the cost of disease treatment and the accessibility of medicine, and will greatly affect the competitiveness and competitive advantage of China in the international biomedical field. Lu Hongbing believes that the moderate opening of international capital investment in stem cell and gene technology will greatly promote the country's research and development process in this field.
Lv Hongbing also suggested in the proposal, can make full use of the "regulations" pudong new area "free trade port in hainan regulations" and other national legislative authorization legislation resources, set up "stem cells, gene diagnosis, and treatment technology development and application of special zone", detailed the system, policies and guidelines, open to foreign investment and other investment subject in the field of investment.

Beijing government report: Accelerate the application of cutting-edge biological technologies such as new cell therapy and gene editing

The fifth session of the 15th Beijing People's Congress opens at the Beijing Convention Center on Jan 6, 2022. Chen Jining, Mayor of Beijing, proposed in his work report: We will further strengthen the "twin engines" of new-generation information technology and medicine and health, promote new breakthroughs in "bottleneck" technologies in the fields of integrated circuits, artificial intelligence and communications, accelerate the breakthrough and application of cutting-edge biological technologies such as new cell therapy and gene editing, and accelerate the industrialization of innovative drugs and high-end medical devices.

Chen Qiyu, member of Shanghai NPC and CPPCC: Make cell therapy drugs affordable for patients and build a multi-payment system

Chen Qiyu, a member of the Standing Committee of the Shanghai People's Political Consultative Conference (CPPCC) and co-CEO of Fosun International, submitted a proposal on "Taking multiple measures to promote Shanghai to become a global cell therapy industry development leader" at the opening of the fifth session of the 13th session of the CPPCC in Shanghai on January 19.
Rudy chan suggested that cell therapy at present, the booming of industry and technology increasingly mature at present, Shanghai is able to establish a series of beneficial to promote cell treatment enterprises in Shanghai for deepening and cultivate high building of Shanghai global cell therapy industry development policies and measures to consolidate the Shanghai in the lead position in the global competition for cell therapy industry.
Chen Qiyu has five specific suggestions:
First, the government departments should introduce a special policy system to support the development of cell therapy industry, including industrial guidance fund, introduction of key talents, scientific research funding support, clinical research support, industrialization incentive policy, industrial land support, tax support, payment system and other aspects.
Second, encourage and support differentiated and distinctive cell therapy technology innovation enterprises to set up businesses in Shanghai, encourage research-oriented hospitals, universities, scientific research institutions and pharmaceutical companies in Shanghai to cooperate in transforming innovative achievements, and optimize the linkage mechanism.
Third, expand the scope of clinical use hospitals, promote the introduction of high-level and differentiated medical institutions into the clinical use of cell therapy, and further promote the development of the industry. It is suggested that relevant departments introduce corresponding policies to encourage qualified medical institutions (including some qualified private hospitals) in Shanghai to carry out clinical capacity construction of cell therapy.
Fourth, build a multi-payment system for cell therapy to make cell therapy drugs available and affordable to more ordinary patients. It is suggested that the municipal medical insurance department explore the establishment of a multi-dimensional medical insurance payment evaluation method for cell therapy products, and give certain degree of medical insurance coverage or special subsidies to cell therapy products declared and marketed as drugs. To support cell therapy enterprises whose products are registered and manufactured in Shanghai to be included in the coverage of special drugs of "Shanghai Welfare Insurance", so as to reduce the payment pressure of patients. The government has cooperated with pharmaceutical companies, health technology platforms and commercial insurance companies to develop innovative payment models such as payment by installment and payment by curative effect.
Fifth, it is suggested that the relevant departments in Shanghai led industry association, drug companies and hospitals, such as the market main body, treatment of medical institutions to carry out commercial cells review certification standard, standard patients and adverse reactions to disposal procedures, drug supply chain and the cold chain transportation management system, cell therapy drug dealers management specification of policy research, form the industry recognized standards.

Hunan: CPPCC members supported the development of stem cell and regenerative medicine industry clusters in Hunan

CPPCC member jin-ming wu, hole peace, Chen Hongzhong, Zheng Ansheng joint recommendations refer to places such as tianjin, shenzhen, hunan charter of stem cell therapy for clinical application of clinical institutions within the free trade area and charge into nature, to attract the national stem cell technology, and the record companies gathered in the zone, forming siphon effect, accelerate the fall to the ground, transformation, incubation and industrialization of scientific research project, To promote the development of stem cell and regenerative medicine industry cluster in Hunan Province. It is suggested that the provincial Food and Drug Administration and relevant competent departments should establish a special task force for drug application. According to the standard of leading enterprises in the strategic emerging industry cluster of stem cell and regenerative medicine in the province, support stem cell companies to apply stem cell drugs quickly, and fill the blank of class A biological innovative drugs in Hunan Province and even in China.

Dalian, Liaoning: Strive to create a complete industrial chain with stem cells

At present, Beijing, Shenzhen and other places are aiming at cells and genes and other major frontier industries to make efforts. Liu Jing, a deputy to the municipal People's Congress, suggested that Dalian take advantage of existing technologies, talents and high-end research platforms to accelerate the transformation of scientific and technological achievements and build a complete industrial chain of "stem cell storage, research and development, and application". As one of the three big biological industrial concentration area in liaoning dalian, has formed an initial differentiation, distinctive medicine + medical cluster, and in such aspects as stem cells, Chinese medicine, genetic testing has accumulated rich core technology and a large number of professional talents, set up national stem-cell research institutions, genetic testing center, international cooperation demonstration base and other high-end research platform, Formed a better industrial application basis.